Stryker (NYSE:SYK) posted a stellar quarter of sales for the robotic surgical system it acquired in its $1.7 billion deal for Mako Surgical.
J.P. Morgan Healthcare Conference
St. Jude Medical delivers ‘solid and uncontroversial’ Q4 prelims
Stryker eyes acquisitions, market share growth in Europe
Stryker CEO Lobo skeptical on ‘repless’ generic sales models
Boston Scientific CEO looks to double emerging market sales
Smith & Nephew CEO Bohuon: Big not always beautiful
Medtronic CEO: ‘Covidien deal will help us do for ORs what we’ve done for cath labs’
GE Healthcare grows profits among declining sales in Q4 and 2013
Renal denervation ‘highly unlikely’ for hypertension, says Medtronic study insider
The future of renal denervation in treatment of hypertension is shaky at best, according to 1 of the principal investigators involved with Medtronic’s disappointing clinical trial.
